Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03529877
Recruitment Status : Recruiting
First Posted : May 18, 2018
Last Update Posted : January 30, 2020
Sponsor:
Collaborators:
FGK Clinical Research GmbH
Granzer Regulatory Consulting & Services
Ticeba GmbH
Information provided by (Responsible Party):
RHEACELL GmbH & Co. KG

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2022